Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a blood test reveal your true age? russian study aims to find out

NCT ID NCT07574359

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to create a 'biological age' calculator specifically for the Russian population. Researchers will collect health, lifestyle, and lab data from 3,500 volunteers aged 18 and older. The goal is to better understand aging and potentially predict age-related disease risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 3,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2023

Expected to finish

Sep 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study cohort comprises a nationally representative sample of the general Russian adult population. We plan to enroll at least 3,500 volunteers (targeting a 1:1 male-to-female ratio) aged 18 years and older. Participants will be systematically recruited across multiple clinical centers in Russia to ensure geographic and social diversity. A key feature of the design is stratified enrollment by 5-year age groups (from 18 to 90+ years), with a target of 200-300 participants per stratum.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Signing the informed consent form to participate in the study. Participant's age was 18 years or older at the time of inclusion in the study. \- Exclusion Criteria: 1. Refusal to participate in the study or to provide informed consent. 2. History or medical records indicating the presence of infectious diseases (Hepatitis C, Hepatitis B, including HBsAg carrier status, HIV infection). 3. Presence of an acute illness/condition, exacerbation of a chronic disease, or surgical intervention within the last month prior to study inclusion. 4. Lack of remission from an oncological disease or ongoing anti-tumor therapy initiated less than three years prior to study inclusion. 5. Severe cognitive or sensory impairments and mental disorders that, in the investigator's opinion, preclude adequate communication with the subject. 6. Severe forms of chronic non-communicable diseases: life-threatening cardiac arrhythmias, chronic heart failure NYHA Class III-IV, left ventricular ejection fraction \<40%, ischemic heart disease CCS Class III-IV, chronic kidney disease Stages 4-5, type 1 diabetes mellitus, type 2 diabetes mellitus with terminal stages of complications, systemic connective tissue diseases, chronic obstructive pulmonary disease with respiratory failure of Grade 1 or higher, bronchial asthma requiring glucocorticosteroid therapy, osteoarthritis Kellgren-Lawrence Grade IV, body mass index (BMI) ≥40 kg/m², as well as documented history of myocardial infarction (MI) or acute cerebrovascular accident (stroke). 7. Pregnancy or lactation (breastfeeding). 8. Any other factors that, in the investigator's opinion, may preclude the participant's inclusion in the study. Additional exclusion criteria for participants undergoing stool sample collection: 9. Use of systemic antibiotics for 3 or more days within the 3 months prior to the study start. 10. Any invasive procedures on the large intestine within the last 3 weeks prior to the study start.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biomarkers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Pirogov Russian National Research Medical University

    RECRUITING

    Moscow, 129226, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.